Tolvaptan therapy of Chinese cirrhotic patients with ascites after insufficient diuretic routine medication responses: a phase III clinical trial

Table 2 Change in body weight on day 7 as primary endpoint of the trial

	(N = 76)	Tolvaptan					P value
	(N = 76)	7.5 mg/day (N = 153)		15 mg/day (N = 301)		Difference between 7.5 mg/day and 15.0 mg/day, 95% CI
	Mean ± SD	Mean ± SD	Difference from placebo, 95% CI	Mean ± SD	Difference from placebo, 95% CI	Difference between 7.5 mg/day and 15.0 mg/day, 95% CI	7.5 mg Tolvaptan versus placebo	15.0 mg Tolvaptan versus placebo	7.5 mg versus 15.0 mg Tolvaptan
Baseline	63.5 ± 12.8	60.6 ± 10.1		62.9 ± 12.0
Day 7	62.3 ± 12.4	58.6 ± 10.1		60.8 ± 12.0
Day 7—baseline	− 1.2 ± 2.2	− 2.0 ± 2.4	− 0.8 (− 1.4, − 0.1)	− 2.2 ± 2.5	− 1.0 (− 1.6, − 0.4)	− 0.2 (− 0.7, 0.3)	0.026	0.001	0.339

ISSN: 1471-230X